News & Updates
Showing Ophthalmology articles
Showing
Show Multimedia Only

Brolucizumab noninferior to aflibercept in nAMD
03 Sep 2022
Treatment with brolucizumab 6 mg, dosed every 4 weeks, is not inferior to aflibercept 2 mg, dosed every 4 weeks, in previously treated participants with neovascular age-related macular degeneration (nAMD) and persistent retinal fluid, a study has shown.
03 Sep 2022

Investigational nasal spray for dry eye disease scores high in phase II trial
16 Aug 2022
The single-dose nicotinic acetylcholine receptor agonist OC-02, administered as an aqueous nasal spray, helps increase tear production and improve eye dryness in patients with dry eye disease (DED), according to data from the phase II PEARL trial.
16 Aug 2022







